Primary surgery with systemic therapy in patients with de novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial
A Soran, V Ozmen, S Ozbas, H Karanlik… - Journal of the American …, 2021 - Elsevier
Background The aim of this randomized clinical trial was to evaluate the overall survival
(OS) data of patients diagnosed with de novo stage IV breast cancer (BC) who received …
(OS) data of patients diagnosed with de novo stage IV breast cancer (BC) who received …
Novel models by machine learning to predict prognosis of breast cancer brain metastases
C Li, M Liu, Y Zhang, Y Wang, J Li, S Sun, X Liu… - Journal of translational …, 2023 - Springer
Background Breast cancer brain metastases (BCBM) are the most fatal, with limited survival
in all breast cancer distant metastases. These patients are deemed to be incurable. Thus …
in all breast cancer distant metastases. These patients are deemed to be incurable. Thus …
Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates
B Liu, H Liu, M Liu - Oncology Reports, 2023 - spandidos-publications.com
Systemic therapy has been viewed as the mainstay for de novo metastatic breast cancer
(dnMBC). However, as dnMBC is highly heterogeneous both biologically and clinically, and …
(dnMBC). However, as dnMBC is highly heterogeneous both biologically and clinically, and …
New frontiers in the treatment of patients with HER2+ cancer and brain metastases: is radiotherapy always useful?
G Scandurra, V Lombardo, G Scibilia, D Sambataro… - …, 2024 - pmc.ncbi.nlm.nih.gov
Simple Summary Brain metastases are a major challenge for patients with HER2+ breast
cancer. Traditional treatments, like radiotherapy, can help but often cause severe side …
cancer. Traditional treatments, like radiotherapy, can help but often cause severe side …
The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (protocol BOMET MF 14-01): a multi-center, prospective registry …
A Soran, L Dogan, A Isik, S Ozbas, DC Trabulus… - Annals of Surgical …, 2021 - Springer
Background More evidence shows that primary surgery for de novo metastatic breast cancer
(BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate …
(BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate …
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis
Patients presenting with de novo stage IV metastatic breast cancer have a complex disease
which is normally treated with palliative intent and systemic therapy. However, there is …
which is normally treated with palliative intent and systemic therapy. However, there is …
Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study
D Liu, J Wu, C Lin, L Andriani, S Ding, K Shen… - Frontiers in …, 2020 - frontiersin.org
Background Metastatic breast cancer (MBC) is a highly heterogeneous disease and bone is
one of the most common metastatic sites. This retrospective study was conducted to …
one of the most common metastatic sites. This retrospective study was conducted to …
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium
M Brandão, D Martins-Branco, C De Angelis… - Breast cancer research …, 2024 - Springer
Purpose We aimed to assess the impact of surgery of primary tumor in overall survival (OS)
of women with de novo metastatic breast cancer. Methods Nationwide, population-based …
of women with de novo metastatic breast cancer. Methods Nationwide, population-based …
Machine learning predicts the prognosis of breast cancer patients with initial bone metastases
C Li, M Liu, J Li, W Wang, C Feng, Y Cai, F Wu… - Frontiers in Public …, 2022 - frontiersin.org
Background Bone is the most common metastatic site of patients with advanced breast
cancer and the survival time is their primary concern; however, we lack accurate predictive …
cancer and the survival time is their primary concern; however, we lack accurate predictive …
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
Background Young age is a poor prognostic factor in early stage breast cancer (BC) but its
value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC …
value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC …